Aurora-Project.eu

E-Learning

E-Learning

Faq e Test

Faq e Test

About Cervical Cancer

About Cervical Cancer

http://www.aurora-project.eu/upload/informa/about-cervical-cancer-1.jpg

About Cervical Cancer

To learn more about your Cervical Cancer national context

http://www.aurora-project.eu/upload/informa/e-learning-2.jpg

Training about screening organization and advocacy strategies

http://www.aurora-project.eu/upload/informa/faq-cervical-cancer-quiz-3.jpg

FAQ & Cervical Cancer Quiz

Section for Women: What Do You Know About Cervical Cancer?

| Prevention!


CERVICAL CANCER SCREENING	HPV VACCINATION
Cervical cancer is the second most common cancer, after breast cancer, among young European women aged 15-44. According to IARC estimates for the year 2004, cervical cancer was diagnosed in approximately 34.300 women in the 27 member states of the European Union and about 16.300 women died of cervical cancer. The social impact of cervical cancer is tremendous, because the majority of cases appear between the ages of 35 and 50, when women are fully active at work and in their families. Within the EU, wide variation in incidence and mortality is observed...Read more »	The link between HPV infection and cervical cancer has allowed the development of several tests to detect its nucleic acids and of prophylactic and therapeutic vaccines. Two prophylactic HPV vaccines against HPV types responsible of cervical cancer are actually licensed in Europe Cervarix® is marketed by GlaxoSmithKline Gardasil® or Silgard® is marketed by Sanofi Pasteur MSD in 19 European countries and by Merck Sharp & Dohme in other Central and Eastern European countries. Read more »